2型糖尿病患者中钠-葡萄糖共转运蛋白2抑制剂相比二肽基肽酶-4抑制剂与新发痛风风险降低相关
香港回顾性人群队列研究纳入43201例2型糖尿病患者,比较SGLT2抑制剂与DPP4抑制剂对新发痛风及全因死亡的影响。中位随访5.59年,SGLT2抑制剂组痛风发病率2.5(95%CI 2.2,2.9)显著低于DPP4抑制剂组5.2(95%CI 4.8,5.8),校正后痛风风险低51%(HR 0.49;95%CI 0.42,0.58;P<0.0001),全因死亡风险低51%(HR 0.49;95%CI 0.42,0.58;P<0.0001)。
要点
- SGLT2抑制剂组痛风发病率2.5(95%CI 2.2,2.9),低于DPP4抑制剂组5.2(95%CI 4.8,5.8)。
- 校正混杂后SGLT2抑制剂与痛风风险低51%相关(HR 0.49;95%CI 0.42,0.58;P<0.0001)。
- SGLT2抑制剂与全因死亡风险低51%相关(HR 0.49;95%CI 0.42,0.58;P<0.0001)。
核心结论
- 与DPP4抑制剂相比,SGLT2抑制剂使用与新发痛风诊断风险降低相关。
研究设计与样本
- 回顾性人群队列研究,纳入2015年1月1日至2020年12月31日在香港接受SGLT2抑制剂或DPP4抑制剂治疗的2型糖尿病患者43201例。
- SGLT2抑制剂组16144例,DPP4抑制剂组27057例,按1:1比例进行倾向性评分匹配,采用单变量和多变量Cox回归模型、竞争风险模型及基于倾向性评分的多种方法分析。
主要发现
- 中位年龄63.23岁(四分位距55.21-71.95),男性占53.74%,自初始药物暴露起中位随访5.59年(四分位距5.27-5.81年)。
- SGLT2抑制剂组痛风发病率为2.5(95%CI 2.2,2.9),DPP4抑制剂组为5.2(95%CI 4.8,5.8)。
- 校正显著的人口学特征、既往合并症、用药及实验室结果后,SGLT2抑制剂与痛风风险低51%相关(HR 0.49;95%CI 0.42,0.58;P<0.0001)。
- 校正后SGLT2抑制剂与全因死亡风险低51%相关(HR 0.49;95%CI 0.42,0.58;P<0.0001)。
- 竞争风险及其他倾向性评分方法的结果保持一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks. METHODS: This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 in Hong Kong. The study outcomes are new-onset gout and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I was performed. Univariable and multivariable Cox regression models were conducted. Competing risks models and multiple approaches based on the propensity score were applied. RESULTS: This study included 43 201 patients [median age: 63.23 years old (Interquartile range, IQR): 55.21-71.95, 53.74% males; SGLT2I group: n = 16 144; DPP4I group: n = 27 057] with a median follow-up of 5.59 years (IQR: 5.27-5.81 years) since initial drug exposure. The incidence rate of developing gout [Incidence rate (IR): 2.5; 95% CI: 2.2, 2.9] among SGLT2I users was significantly lower than DPP4I users (IR: 5.2; 95% CI: 4.8, 5.8). SGLT2I was associated with 51% lower risks of gout (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) and 51% lower risks of all-cause mortality (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory results. The results remained consistent on competing risk and other propensity score approaches. CONCLUSIONS: SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use.
引用
- Zhou J, Liu X, Chou OH, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). 2023. PMID: 36066415. doi:10.1093/rheumatology/keac509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。